Financial Performance - In 2024, the company achieved a revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - The net profit excluding non-recurring items was 4.523 billion CNY, reflecting a 20.18% increase from 3.764 billion CNY [2] - Operating cash flow net amount was 4.297 billion CNY, a growth of 22.68% [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share were 2.66 CNY, up 16.16% year-on-year [2] Business Structure and Efficiency - Industrial revenue accounted for 36.14% of total revenue, with an industrial revenue growth rate of 5.30% [3] - The gross margin for industrial products was 65.93%, an increase of 1.69 percentage points [3] - Sales expenses decreased by 2.26% and management expenses decreased by 1.98% compared to the previous year [3] - Total assets at the end of the reporting period were 52.914 billion CNY, with net assets attributable to shareholders at 38.832 billion CNY and a debt-to-asset ratio of 26.55% [3] Dividend Distribution - The company distributed a cash dividend of 11.85 CNY per 10 shares (before tax) based on a total share capital of 1,784,262,603 shares [4] - A special dividend of 12.13 CNY per 10 shares (before tax) was completed in November 2024, totaling 2.164 billion CNY [4] - The total cash dividend for 2024 was 23.98 CNY per 10 shares, amounting to 4.279 billion CNY, which represents 90.09% of the net profit attributable to shareholders [4] Pharmaceutical Business Highlights - The pharmaceutical segment focused on pain management and launched a new pain management model [5] - Clinical research on core products showed steady progress in areas like diabetic foot and skeletal pain [6] - Marketing initiatives included the successful promotion of a sports IP to enhance brand youthfulness [6] - The production efficiency was improved through the establishment of an online business process [6] Health Products and Channel Development - The health products segment maintained a leading market share in toothpaste and high brand penetration in oral care [7] - The company optimized its channel strategy, strengthening traditional channels while exploring new retail formats [8] Provincial Pharmaceutical Company Performance - In 2024, the provincial pharmaceutical company achieved a revenue of 24.607 billion CNY, a year-on-year increase of 0.48% [9] - Non-pharmaceutical business segments like medical devices and special medical foods saw a sales growth of 14% [9] - The OTC segment experienced an 18% sales increase, while the new specialty drug pharmacies grew by 29% [9] - Future plans include enhancing customer health services and integrating upstream and downstream resources [10]

Group 1: Investor Relations Activity - The meeting was categorized as a telephone conference [2] - Participants included representatives from Orient Securities Company Limited [2] - The meeting took place on May 19, 2025, at the company's headquarters [2] Group 2: Company Representatives - The meeting was attended by the board secretary, Qian Yinghui, and other investor relations personnel [2] - Securities affairs representative was Li Mengjue [2] - Other attendees included Zhang Yuxin and Yang Kexin [2] Group 3: Main Content of the Meeting - The primary focus was to understand the company's production and operational status [2] - Relevant questions regarding the company's performance were discussed [2]

Group 1: Pharmaceutical Business Performance - In 2024, the pharmaceutical segment achieved a revenue of 6.924 billion CNY, a year-on-year increase of 11.8% [2] - The sales revenue of Yunnan Baiyao aerosol exceeded 2.1 billion CNY, growing over 26% [2] - The sales of other traditional Chinese medicine products, such as Pudilan's anti-inflammatory tablets, reached nearly 200 million CNY, with a significant growth of over 22% [4] Group 2: Traditional Chinese Medicine Supply Chain Development - Yunnan Baiyao is committed to being the "chain leader" in the traditional Chinese medicine supply chain in Yunnan Province [3] - The company established a specialized traditional Chinese medicine seed company to control genetic resources [4] - The "Shuzhi Cloud Medicine" platform was launched, facilitating transactions exceeding 100 million CNY [4] Group 3: Oral Care Product Sales and Market Strategy - The health product segment generated 6.526 billion CNY in revenue, with a year-on-year growth of 1.6% [5] - Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [5] - The company is enhancing its channel strategy by optimizing traditional offline channels and exploring new retail formats [5] Group 4: Q1 2025 Financial Performance - In Q1 2025, the company reported a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [7] - The net profit attributable to shareholders was 1.935 billion CNY, growing by 13.67% [7] - The cash flow from operating activities reached 714 million CNY, up 35.39% year-on-year [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024 and completed its I/IIa phase clinical summary report in November [8] - The company’s subsidiary received approval for the clinical trial of INR102, aimed at treating metastatic castration-resistant prostate cancer [9]

Group 1: Company Overview - Yunnan Baiyao Group Co., Ltd. is engaged in production and operation activities [1] - The investor relations activity aimed to understand the company's operational status [2] Group 2: Investor Relations Meeting Details - The meeting took place on May 19, 2025, at the company headquarters [2] - Participants included representatives from Matthews International Capital Management LLC and Yunnan Baiyao's investor relations team [2] Group 3: Key Participants - Securities affairs representative: Li Mengjue [2] - Investor relations management: Zhang Yu, Yang Kexin [2]

Group 1: Company Strategy and Innovation - The company leverages flexible production technology to meet the increasing demand for personalized furniture while maintaining cost control [2] - The introduction of the "AI Design Factory" aims to enhance operational efficiency and transform the business model through systematic AI deployment [2][3] - The launch of integrated wall and cabinet products represents an advancement in the company's "whole-house customization" model, enhancing overall design coherence [3] Group 2: Financial Performance and Shareholder Returns - The company has maintained a cash dividend of 9 RMB per 10 shares for two consecutive years, with plans to continue this trend based on operational performance [4] - The profit distribution plan for 2024 aims for a total cash dividend of no less than 100 million RMB, reflecting a commitment to shareholder returns [4] - The company reported a significant net cash flow exceeding 1.1 billion RMB over the past two years, indicating strong cash-generating capabilities [4] Group 3: Cost Management and Operational Efficiency - The company reduced its workforce by 16.22% to 7,689 employees by the end of 2024 as part of ongoing organizational restructuring [5] - Continuous cost control measures and operational efficiency optimizations have been implemented to enhance profitability [5][7] - The integration of a comprehensive knowledge base covering 300,000 product types and 3 million housing designs has improved operational processes and customer interaction [5][7] Group 4: Market Expansion and Future Plans - The company plans to expand its market presence through a "1+N" city development model and aims to open 500 stores across 9 cities [6][7] - The strategic focus for 2025 includes enhancing product quality, optimizing supply chain management, and leveraging AI technology for overseas business expansion [6][7] - The company is committed to adapting to the fourth-generation housing market by developing suitable products and services [8]

Group 1: Financial Performance - The main reasons for the decline in Q1 2025 performance include an increase in taxes and additional expenses: taxes increased by CNY 31.09 million due to higher consumption tax on large-displacement motorcycles; R&D expenses rose by CNY 20.92 million due to new product development and certification costs; sales expenses increased by CNY 15.34 million due to higher advertising costs. Excluding these factors, operational performance remained stable [2] - For the first four months of 2025, the motorcycle industry saw domestic sales of 1.4277 million units, a decrease of 0.8% year-on-year, while exports reached 3.9347 million units, an increase of 27.8% year-on-year [3] Group 2: Market Overview - In 2024, the sales distribution by region was as follows: Asia approximately 45%, North America approximately 17%, Europe approximately 16%, South America approximately 11%, and Africa approximately 10%. Major sales regions for large-displacement motorcycles are Europe and Asia, with potential growth expected in Europe and South America [2] - The company's market share in the U.S. was less than 1% in 2024, and current changes in the U.S. market have minimal direct impact on the company, but may affect future expansion efforts in the U.S. motorcycle market [3] Group 3: Sales Performance - For the first four months of 2025, the company reported domestic sales of 79,300 units, a year-on-year increase of 31%, with large-displacement sales of 27,900 units, up 14.3% year-on-year. However, external sales decreased by 24.4% to 59,500 units, with large-displacement sales of 16,400 units, a growth of 2.7% year-on-year. The decline in external sales was primarily due to reduced sales in the Turkish market [3] Group 4: Investor Relations - The company is considering increasing dividend payouts to enhance investor returns, with a focus on future development and profitability. Starting from 2024, the company has introduced mid-term dividends and plans to authorize the board to develop a mid-term dividend plan for 2025 [4]

编号：2025-001 | | □特定对象调研□分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访√业绩说明会 | | | □新闻发布会□路演活动 | | 类别 | □现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2025 年 5 月 21 日 (周三) 下午 14:30~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、副总经理兼董事会秘书、财务负责人刘宜峰 | | 员姓名 | 2、证券事务代表李莉莉 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、公司还有继续拓展的想法吗？定增什么时候完成呢？二级市 | | | 场跌跌不休，能不能出一些措施稳定股价呢？ | | | 尊敬的投资者，您好！公司始终关注行业趋势与市场机遇， | | | 并持续做大做强主营业务。公司正在积极开拓市场，努力 ...

证券代码：002508 证券简称：老板电器 公司始终秉持"稳健经营、共赢发展"理念，长期坚持每 年两次现金分红政策，并严格履行分红比例不低于 50%的 承诺。未来，在经营业绩持续增长、现金流充裕的前提下， 公司将优先考虑提升分红水平，进一步强化股东回报力 度，充分彰显管理层对业务前景的信心及对投资者权益的 重视。 4、公司如何看待厨房电器行业的结构性变化？ 面对行业从增量转向存量的结构性调整，公司将其视为战 略机遇期，通过创新驱动与效率提升实现突破。一方面， 公司深化电商渠道投入，抢占线上流量高地；另一方面， 以集成化、套系化产品为核心，打造差异化竞争力。同时， 依托品牌与技术优势，公司积极整合存量市场资源，持续 扩大市场份额，巩固行业龙头地位。 杭州老板电器股份有限公司 投资者关系活动记录表 编号：2025-001 投资者关系活动 类别 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 现场参观 ☑其他 （公司投资者接待日活动） 参与单位名称及 人员姓名 公司投资者 时间 2025 年 5 月 19 日 地点 公司全球烹饪艺术中心会议室 上市公司接待人 员姓名 公司管理层 投资 ...

| | 目估算总投资金额 | 305.2 亿元为依据，项目资本金为总投资的 | 35％， | | --- | --- | --- | --- | | | 其余 | 65%为银行贷款。公司按持有广惠公司 51%股比承担资本金出 | | | | 资，约 | 54.48 亿元（最终以项目竣工决算价为准），建设期为 5 | 年。 | | | | 公司将统筹协调做好资金保障，通过拓宽融资渠道，积极寻求低成 | | | | | 本融资，确保项目工程建设资金需求。具体详情，可以查阅公司公 | | | | | 告（公告编号：2025-006）。 | | | | 问 | 3：广惠高速改扩建的必要性 | | | | | 答：广惠高速位于珠三角交通枢纽核心区域，交通流量大，其通行 | | | | | 费收入能够为公司发展提供稳定的收入支撑。增资投资广惠改扩建 | | | | | 工程有利于扩大提升公司的高速公路资产规模，聚焦高速公路投资 | | | | | 建设的主责主业，抓住"十四五"期间交通运输发展的黄金时期， | | | | | 推动公司可持续高质量发展。广惠高速实施改扩建后可核定收费经 | | | | | 营期，广惠公司得 ...

证券代码：300365 证券简称：恒华科技 北京恒华伟业科技股份有限公司 2、AI 设计助手"道亨智询"的使用场景和收费模式？ 答：输电线路设计涉及地形地貌、气候条件、经济成本与 技术发展等诸多复杂因素，开展业务需严格遵循大量标准规定 与规程规范，对从业人员的专业性和行业经验有较高要求。基 于此行业特性，公司集成 DeepSeek、Qwen、Llama、ChatGLM 等多个大语言模型，构建行业知识库，将行业标准规范、法律 法规、历史工程数据、技术支持问答数据等关键信息输入其中 学习，并发布 AI 设计助手"道亨智询"，可全面满足电气-结 构-基础多专业设计人员智能问答需求，提升设计效率。目前 投资者关系活动记录表 编号：2025-002 投资者关系活动 类别 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称 国泰海通证券、幸福人寿 2 家机构投资者。 时间 2025 年 5 月 21 日 地点 公司会议室 上市公司接待人 员姓名 董事会秘书 丰 丹 技术专家 隗 刚 证券事务代表 邓雅静 投资者关系活动 主要内容介绍 1、AI技术对公司业务的 ...